Annual Reports in Medicinal Chemistry

<p>1 Recent advances in the discovery of GSK-3 inhibitors and a</p> <p>perspective on their utility for the treatment of Alzheimer’s</p> <p>disease</p> <p>Robert G. Gentles, Shuanghua Hu,</p> <p>and. Gene Dubowchik</p> <p>2 Advances in the Development of Nitric Oxide Synthase Inhibitors</p> <p>Shawn Maddaford, Subhash</p> <p>Annendi, Jailall Remnauth, and</p> <p>Suman Rakhit</p> <p>3 Small Molecule Protein–Protein Interaction Inhibitors as</p> <p>Therapeutic Agents for Neurodegenerative Diseases: Current</p> <p>Progress and Future Hurdles</p> <p>Simon Haydar and Warren Hirst </p> <p>4 Case History: Chantix (varenicline tartrate) a Nicotinic Partial</p> <p>Agonist Aid to Smoking Cessation</p> <p>Jotham W. Coe, Hans Rollema and</p> <p>Brian T. O’Neill </p> <p>5 Case History on Tekturna® /Rasilez® (Aliskiren), a Highly</p> <p>Efficacious Direct Oral Renin Inhibitor as a New Therapy for</p> <p>Hypertension</p> <p>Juergen Maibaum and David Feldman</p> <p>6 Advances in Vasopressin Receptor Agonists and Antagonists Thomas Ryckmans </p> <p>7 The Emergence of GPR119 Agonists as Anti-diabetic Agents Robert Jones </p> <p>8 Non-peptide Ligands for the Gonadotropin Receptors Nicole van Straten, Marco Timmers</p> <p>9 Recent Advances in Coagulation Serine Protease Inhibitors</p> <p>Mimi Quan and Joanne Smallheer</p> <p>10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors Mark Player and Carl Manthey</p> <p>11 Recent Advances in the Discovery of CB2 Selective Agonists Jayant Thatte, Sangdon Han, and Rob Jones </p> <p>12 Advances in the Discovery of Small Molecule JAK3 Inhibitors Stephen Wrobleski </p> <p>13 Recent Advances in Adenosine Receptor (AR) Ligands in</p> <p>Pulmonary Diseases</p> <p>Jeff Zablocki and Rao Kalla </p> <p>14 Recent Progress in the Development of Small Molecule Inhibitors</p> <p>of Insulin-like Growth Factor Receptor (IGF-1R) Kinase Dinesh Vyas and Mark Wittman </p> <p>15 Case History: Discovery of Ixabepilone (IXEMPRA[TM]), a First-inclass</p> <p>Epothilone Analogue for Treatment of Metastatic Breast Cancer</p> <p>Robert M. Borzilleri and Gregory D.</p> <p>16 Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics Stefan Peuker and Karen Miller-Moslin </p> <p>17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-</p> <p>3-Kinases (PI3Ks)</p> <p>John M. Nuss, Amy Lew Tsuhako</p> <p>and Neel K. Anand Exelixis</p> <p>18 Anti-infective Activity of Artemisinin and its Semi-synthetic</p> <p>Derivatives John G. D'Angelo</p> <p>19 Recent Advances in the Inhibition of Bacterial Type II</p> <p>Topoisomerases</p> <p>Greg Bisacchi & Jacques Dumas</p> <p>20 Progress Towards the Discovery and Development of Specifically</p> <p>Targeted Inhibitors of Hepatitis C Virus</p> <p>Nicholas A. Meanwell John F.</p> <p>Kadow and Paul M. Scol </p> <p>21 Inhibitors of Nuclear Hormone Receptor/Steroid Receptor</p> <p>Coactivator Interactions</p> <p>Terry Moore, John Katzenellenbogen </p> <p>22 Safety Testing of Drug Metabolites Tom Thompson </p> <p>23 A Path to Innovation: Gene Knockouts Model New Drug Action Brian Zambrowicz </p> <p>24 Discovery of Novel Positron Emission Tomography (PET) Tracers Dennis McCarthy </p> <p>25 The Use of Isotopically Labeled Compounds in Drug Discovery (Chad) Charles S. Elmore</p> <p>26 Mechanism based inhibition of CYP3A4 and other cytochromes P450 Bernard Murray </p> <p>27 Nonclinical Toxicogenomics in the Pharmaceutical Environment Bruce D. Car </p> <p>28 To Market, To Market 2008 Shridhar Hegde and Michelle Schmidt</p>